The Stimulus Bill and Funding Opportunities for Cleantech Startups

[Editor’s note: Scott Wolfe wrote this article with Edward W. Correia, counsel in Latham & Watkins’ Washington, D.C. office.]

On February 17, 2009, President Barack Obama signed into law the largest funding bill in the history of the United States, the American Recovery and Reinvestment Act of 2009. The law provides almost $800 billion in spending to stimulate the recovery of the U.S. economy, a large portion of which is directed toward encouraging the development of energy in ways that protect the environment. The recovery act expands upon a number of existing programs and creates some new ones. Startup companies that are focused on cleantech, as well as venture capital firms that are interested in investing in cleantech companies, should explore the opportunities created by this highly significant legislation.

The federal government has always been an attractive supplemental funding source for cleantech technology, particularly because of the long-standing public interest in developing manufacturing and energy-producing technology that protects the environment. The federal government administers a number of research grant programs through various agencies. Most federal funds are provided to universities and other non-profit research institutions. However, some programs make research funds available to for-profit entities. That has been true, for example, in the case of Small Business Administration research and development grants to small businesses developing cutting-edge technology. These types of programs have been expanded by the economic stimulus package and now include, for example:

—$3.4 billion for the Department of Energy (“DOE”) to fund R&D on fossil energy, clean coal and carbon capture projects
—$2.5 billion for DOE to fund R&D on energy efficiency and renewable energy
—$2.0 billion for manufacturers to develop advanced batteries
—$400 million in additional funding for the projects to reduce foreign imports of energy

The recovery act also includes $6 billion in new funds for

Author: Scott N. Wolfe

Scott Wolfe is a partner in the San Diego office of Latham & Watkins. Mr. Wolfe advises start-up and emerging businesses and public companies, particularly in the life sciences and high-technology industries. He regularly represents companies and investment banking firms in public offerings, private placements, venture capital financings, real estate investment trusts, debt offerings, corporate partnering arrangements, and mergers and acquisitions. Mr. Wolfe is a member of the American, California and San Diego Bar Associations. He is the former Chairman and current trustee and member of the Executive Committee of Rady Children's Hospital and Health Center in San Diego. He is a trustee of BIOCOM, CONNECT and the Corporate Directors Forum, Counsel for the Sanford Consortium of Regenerative Medicine and member of the Dean's Advisory Council of the Rady School of Management at UCSD. Mr. Wolfe is a former owner of the San Diego Padres (1990–1999). He is an Adjunct Professor of Law at USD Law School teaching a class in “Advanced Corporate Transactional Skills” and teaches classes in venture capital and mergers and acquisitions at the Rady School. Mr. Wolfe is a recommended as a “leading lawyer” in Chambers USA 2014 – Capital Markets: Debt & Equity – California and in Life Sciences: California and is described as "extremely experienced and very bright; there is really not a lot that you can come up against that he hasn't been involved in." He is the recipient of the 2013 Thomas F. Carter Award, the highest leadership and philanthropic award given by Rady Children’s Hospital and Health Center – San Diego, and was named as one of the “important M&A practitioners” by The Legal 500 US.